92 related articles for article (PubMed ID: 1343147)
1. [The dynamics of the hormonal and tumor marker levels in response to adrenaline administration in lung cancer patients].
Khudoleĭ VN; Velichko SA
Vopr Onkol; 1992; 38(10):1209-17. PubMed ID: 1343147
[TBL] [Abstract][Full Text] [Related]
2. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer].
Li R; Li R; Wang Y
Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296
[TBL] [Abstract][Full Text] [Related]
3. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E
Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of CYFRA 21-1 in malignant and benign pleural effusions.
Toumbis M; Rasidakis A; Passalidou E; Kalomenidis J; Alchanatis M; Orphanidou D; Jordanoglou J
Anticancer Res; 1996; 16(4A):2101-4. PubMed ID: 8712750
[TBL] [Abstract][Full Text] [Related]
5. Tissue polypeptide antigen in bronchogenic carcinoma.
Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O
Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159
[TBL] [Abstract][Full Text] [Related]
6. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels.
Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E
Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851
[TBL] [Abstract][Full Text] [Related]
7. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
[TBL] [Abstract][Full Text] [Related]
8. [The diagnostic values of CA242 combining other tumor markers for lung cancer].
Zhang S; Ma Y; Yang X
Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851
[TBL] [Abstract][Full Text] [Related]
9. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
10. [Main indicators of hormonal status in lung diseases].
Zyrianov BN; Velichko SA; Kuznetsov VV; Siianov VS
Med Radiol (Mosk); 1988 Aug; 33(8):31-4. PubMed ID: 2842572
[TBL] [Abstract][Full Text] [Related]
11. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and IL-2R in lung cancer.
Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL
Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891
[TBL] [Abstract][Full Text] [Related]
13. Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma.
Kong F; Jirtle RL; Huang DH; Clough RW; Anscher MS
Cancer; 1999 Nov; 86(9):1712-9. PubMed ID: 10547543
[TBL] [Abstract][Full Text] [Related]
14. [Tumor markers--a diagnostic and prognostic test].
Moroz GS; Dryzhak VI; Dykan IN; Kudin AT; Iaremenko AV; Solomianin VI
Vopr Onkol; 1991; 37(3):289-93. PubMed ID: 1851587
[TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
16. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulins and complement components in patients with lung cancer.
Oner F; Savaş I; Numanoğlu N
Tuberk Toraks; 2004; 52(1):19-23. PubMed ID: 15143368
[TBL] [Abstract][Full Text] [Related]
18. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.
Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N
Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038
[TBL] [Abstract][Full Text] [Related]
19. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of tumor markers CYFRA 21-1 and neuron-specific enolase in lung cancer].
Kushlinskiĭ NE; Liubimova NV; Lemeshko AO; Vasil'ev AV; Davydov MI
Biull Eksp Biol Med; 1997 Jan; 123(1):98-100. PubMed ID: 9213472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
